This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Growth stocks are having a moment. Several small- and mid-cap stocks have suddenly jumped 40% or more in the past 30 days.

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

The GLP-1 Exit Plan by Holli Bradish-Lane Holli Bradish-Lane, founder of Iron Crucible Health Coaching, is making waves in ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...